ArticleJournal of oral biology and craniofacial research
Biogenic synthesis of copper oxide nanoparticles using
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Copper-based biomaterials are increasingly investigated for bone tissue engineering due to their osteogenic and angiogenic properties. Green synthesis using plant extracts offers an eco-friendly route for producing biocompatible nanoparticles. This study aimed to synthesize copper oxide nanoparticles (CuO NPs) using Methods: CuO NPs were synthesized by reacting copper nitrate trihydrate with A. calcarata leaf extract under alkaline conditions, followed by calcination. The nanoparticles were characterized using SEM, TEM, XRD, and FTIR to confirm morphology, crystallinity, and functional group interactions. C3H10T1/2 murine mesenchymal stem cells were used to assess cytocompatibility (MTT assay, FDA staining), osteogenic differentiation (Alizarin Red S staining and quantification), and gene expression (qRT-PCR for Runx2, Col-I, and ALP). Results: SEM and TEM revealed aggregated, spherical nanoparticles of <100 nm, while XRD confirmed crystalline monoclinic CuO and FTIR indicated phytochemical capping. MTT and FDA assays showed CuO NPs were cytocompatible up to 50 μg/mL, with dose-dependent cytotoxicity observed at higher concentrations. Under osteogenic conditions, cells treated with 50 μg/mL CuO NPs displayed significantly enhanced mineral deposition compared to controls. Gene expression analysis demonstrated upregulation of Runx2, Col-I, and ALP, confirming promotion of osteogenic differentiation. Conclusion: Biogenically synthesized CuO NPs using A. calcarata extract are structurally pure, biocompatible at defined concentrations, and capable of enhancing osteoblast differentiation by stimulating matrix mineralization and osteogenic gene expression. These findings position A. calcarata-mediated CuO NPs as sustainable, multifunctional nanomaterials with promising applications in bone tissue engineering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.